National Patient Safety Alert – ADHD drugs
Written by AlisonFreemantle on Friday 13th October 2023
Shortage of methylphenidate prolonged-release capsules and tablets, lisdexamfetamine capsules, and guanfacine prolonged-release tablets
The Patient Safety Alert can be viewed here:
At present, the supply disruptions are expected to resolve at various dates between October and December 2023.
The supply disruption of these products is caused by a combination of manufacturing issues and an increased global demand.
Other ADHD products remain available but cannot meet excessive increases in demand.
The products affected are:
Methylphenidate:*
- Equasym XL® 10, 20 and 30 mg capsules
- Xaggitin XL® 18 and 36 mg prolonged-release tablets
- Concerta XL® 54 mg prolonged-release tablets
- Xenidate XL® 27 mg prolonged-release tablets
Lisdexamfetamine:
- Elvanse® 20, 30, 40, 50, 60 and 70 mg capsules
- Elvanse® Adult 30, 50, and 70 mg capsules
Guanfacine:
- Intuniv® 1, 2, 3 and 4 mg prolonged-release tablets
Hampshire & Isle of Wight ICB have put together some resources for patients and GP surgeries. Patient leaflets and resources are available on the ICB website here:
The patient leaflets can be found towards the bottom of the page in the section called ‘medicines used to treat ADHD’